2018ForumIssue1

Cutaneous Lymphoma Foundation 2018 Issue 1 RESEARCH IN CUTANEOUS LYMPHOMA: A BROAD VIEW Since the development of the “scientific method,” people have been engaged in research in efforts to answer questions, solve problems, and add to our overall knowledge. Nowhere is this more evident than in the medical field, and in the study of cutaneous lymphoma. Ongoing research efforts in cutaneous lymphoma focus on two broad areas highlighted below where significant advancements have improved treatments and outcomes of patients. Pre-clinical/Basic science: This is the broadest of the research categories. Pre-clinical/ basic science data is constantly being generated by molecular biologists, cancer biologists, biochemists, pharmacologists, among others. Demonstrating how proteins and molecules interact with one another within a single cell, how cells interact with their surroundings, and how cancer cells are different from normal cells are some of the ways we can better understand disease and through that knowledge, develop potential therapeutics. It is also in this setting where we test potential new drugs outside of the human to first assess efficacy and potential side effects. In cutaneous lymphoma there is a stream of data being published that provides new insights into its development. For example, investigations into the role of small RNA molecules (microRNA) showed that altering microRNA levels within cells affects the growth of cutaneous lymphoma. Additionally, research on epigenetic modifiers (regulators of gene levels) has shown changes in several of these proteins. Furthermore, with the advent of high-throughput genomic sequencing, multiple scientists have used this technology to better understand the possible genetic anomalies in cutaneous lymphoma. Sequencing of the entire genome within cutaneous lymphoma has generated large amounts of data and has allowed researchers to focus their efforts on specifically altered molecular pathways. Currently, researchers are focusing on growth From the President and the Chief Executive Officer. ............................................................. 3 2-Day Patient Conference............................. 4 My Journey with Cutaneous Lymphoma: A Caregiver’s Story.................................................... 6 Clinical Trial Update: FLASH Study. ............... ..7 Skincare Corner Q&A. .......................................... 8 Upcoming Events............................................ 11 So, What Does the Foundation Really Do For Me? ....................................................................12 ce...........................................................12 Research...continued on page 5 Cutaneous Lymphoma Foundation

RkJQdWJsaXNoZXIy NzU3MjY=